ABPI response to DHSC antimicrobial resistance research funding

The Department of Health and Social Care have announced £39 million of funding for antimicrobial resistance research. 

We look forward to NHS plans for taking forward the learnings from the pilot, and the development of a more permanent solution for the development of new treatments against AMR. Claire Machin, ABPI Executive Director of International Policy and UK Competitiveness

Claire Machin, ABPI Executive Director of International Policy and UK Competitiveness said: “This is a positive step for research into finding long term solutions for AMR. Beyond research there is an essential need for collaboration, on a global scale, that allows research efforts to be developed into effective antibiotics available for all.


“Alongside today’s announcement, England has also been leading the way as the first country to implement a pilot scheme for incentivising the development of new treatments using an innovative payment arrangement, but the UK acting on it's own cannot combat AMR. Multiple global solutions which bring together governments, healthcare systems and the pharmaceutical industry are needed at scale if we are to stand a chance against AMR.


“We look forward to NHS plans for taking forward the learnings from the pilot, and the development of a more permanent solution for the development of new treatments against AMR.”

TAGS
  • AMR

Last modified: 20 September 2023

Last reviewed: 20 September 2023

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.